Medicinal and edible traditional Chinese medicine weight-losing and lipid-lowering composition as well as preparation method and application thereof

Abstract

The invention discloses a medicinal and edible traditional Chinese medicine weight-losing and lipid-lowering composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions.The composition is prepared from, by weight, 20-30 parts of lotus leaves, 12-24 parts of hawthorn fruits, 15-25 parts of poria cocos, 3-10 parts of licorice roots, 5-6 parts of pericarpium citri reticulatae, 6-8 parts of cassia seeds, 5-8 parts of Chinese yam, 1-3 parts of fresh ginger and 1-3 parts of Chinese dates. The preparation method has the beneficial effects that the lotus leaves, the hawthorn fruits, the cassia seeds and the like have the effects of removing stasis, promoting digestion, reducing lipid, losing weight and the like, and are monarch and ministerial drugs for obesity, hyperlipidemia and the like; poria cocos, licorice, dried orange peel and other medicines have the effects of invigorating spleen, promoting diuresis, regulating qi-flowing for eliminating phlegm, removing dampness and turbidity evil in the body, enhancing transportation and transformation functions of spleen and stomach, providing a basis for playing roles of monarch and ministerial medicines, creating a good internal environment for the body, being reasonable in compatibility of the whole formula, and combining purgation and tonification, and jointly achieving the effects of eliminating dampness, dissolving turbidity, invigorating spleen, removing food retention, reducing fat and losing weight. The traditional Chinese medicine composition has a good improvement effect on obesity, hyperlipemia, spleen and stomach food retention, excessive dampness and excessive phlegm and other diseases.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine compositions, and in particular relates to a traditional Chinese medicine composition for weight loss and lipid reduction having both medicinal and edible properties, and a preparation method and application thereof. Background Art

[0002] Obesity, defined by the World Health Organization as a chronic disease, is a condition characterized by significant overweight, excessive fat accumulation, and a thick layer of fat. With the rapid growth of the global economy and improvements in living standards, changes in diet, the prevalence of refined foods, and a decrease in physical activity have led to a significant increase in the incidence of obesity, making it a leading global health issue. Obesity can be categorized into three types based on its causes: simple obesity, secondary obesity, and medication-induced obesity.

[0003] Simple obesity is the most common type of obesity, accounting for 95% of the obese population. It is usually not associated with any disease. This type of obese person has an even distribution of fat, no endocrine disorders or metabolic disorders, and family heredity is an important factor. Simple obesity is divided into constitutional obesity and overeating obesity. Constitutional obesity is related to genetics, with an increase in the number of fat cells and is related to overnutrition before the age of 25. Its metabolic rate is low, with anabolism exceeding catabolism. Overeating obesity, also known as nutritional obesity, is often caused by the patient intentionally or unintentionally eating too much high-fat and high-sugar food. This type of obesity tends to be distributed in the trunk and is more common than constitutional obesity. People with constitutional obesity may also develop acquired obesity and become mixed obesity, which has a poor prognosis.

[0004] Simple obesity is a chronic low-grade inflammatory state, and its pathogenesis is closely related to endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress, and macrophage polarization in the body. Both Chinese and Western medicine have their own intervention and treatment methods for this disease, but modern medicine believes that the treatment of obesity is a comprehensive treatment that combines dietary nutritional structure adjustment, exercise, mental health, and medication, which requires high patient execution and compliance. In drug treatment, metformin and the pancreatic lipase inhibitor orlistat can cause certain gastrointestinal adverse reactions. In view of these adverse reactions, finding well-tolerated drugs to prevent and treat obesity is an urgent need for patients.

[0005] "Medicine can be used in food, and food can also be used as medicine" is a distinctive theory in Traditional Chinese Medicine (TCM) for disease prevention and treatment. The Yellow Emperor's Classic of Internal Medicine, Su Wen, states, "Since ancient times, sages have created soups, liquors, and wines as a precaution. When morality declines and evil spirits arrive, they are taken for complete relief." It believes that soups and wines made from grains can be eaten or drunk, and can also treat illnesses. The Dietary Materia Medica was the first to separate dual-use medicinal and edible substances from traditional herbal medicine. The full text records 260 dual-use medicinal and edible substances, with their properties, dietary preferences, dietary taboos, and recipes noted. Later generations of physicians have refined the understanding of these substances and their uses, with treatises such as the Compendium of Materia Medica and Edible Materia Medica. Modern experts and scholars, combined with the study of ancient texts, have compiled books on medicated diets and dietary therapy, such as Chinese Pharmacy and Chinese Dietary Therapy, ushering in a standardized development of the dual-use medicinal and edible concept.

[0006] The catalogue of edible and medicinal herbs, currently published by the National Health Commission of the People's Republic of China, lists 110 Chinese herbs with edible and medicinal properties. Some of these herbs may improve obesity treatment outcomes by regulating insulin signaling, lipid metabolism, microbial balance, combating oxidative stress, reducing inflammation, and increasing insulin sensitivity. Furthermore, these herbs exhibit minimal adverse reactions, are highly safe, have high patient compliance, and can be used long-term. This suggests that these herbs possess therapeutic advantages, including high efficacy, low toxicity, multi-target action, and multiple levels of efficacy.

[0007] Compared to single herbs, traditional Chinese medicine (TCM) compound formulas can exert therapeutic effects in multiple pathways and directions, acting on multiple targets, resulting in greater efficacy. This combined effect can more comprehensively regulate body functions and has the unique characteristic of modulating imbalances across various organs. Since most cases of simple obesity lack clear clinical manifestations, TCM formulas and their combinations can regulate the body's internal organs and the metabolism of qi, blood, and body fluids by strengthening the spleen and removing dampness, promoting qi and promoting diuresis, and harmonizing qi and blood, promoting the excretion of accumulated metabolic products, and accelerating metabolism. Therefore, TCM herbs with "medicine and food of the same origin" represent a treasure trove of potential for the treatment of obesity. Summary of the Invention

[0008] The technical problem to be solved by the present invention is how to provide a Chinese medicinal composition with both medicinal and edible properties for preventing and improving obesity and a preparation method thereof.

[0009] The present invention solves the above technical problems through the following technical means:

[0010] The first aspect of the present invention provides a traditional Chinese medicine composition with weight loss and lipid-lowering effects, which comprises the following components in parts by weight, calculated as raw materials: 20-30 parts of lotus leaves, 12-24 parts of hawthorn, 15-25 parts of poria cocos, 3-10 parts of licorice, 5-6 parts of tangerine peel, 6-8 parts of cassia seeds, 5-8 parts of yam, 1-3 parts of ginger, and 1-3 parts of jujube.

[0011] Preferably, based on the raw materials, the ingredients include the following parts by weight: 30 parts of lotus leaves, 24 parts of hawthorn, 20 parts of poria, 10 parts of licorice, 5 parts of tangerine peel, 6 parts of cassia seeds, 8 parts of yam, 3 parts of ginger, and 1 part of jujube.

[0012] Preferably, based on the raw materials, the ingredients are as follows in parts by weight: 20 parts of lotus leaves, 12 parts of hawthorn, 15 parts of poria, 3 parts of licorice, 6 parts of tangerine peel, 7 parts of cassia seeds, 5 parts of yam, 2 parts of ginger, and 2 parts of jujube.

[0013] Preferably, based on the raw materials, the following components are included in parts by weight: 24 parts of lotus leaves, 20 parts of hawthorn, 24 parts of poria, 6 parts of licorice, 6 parts of tangerine peel, 8 parts of cassia seeds, 6 parts of yam, 3 parts of ginger, and 3 parts of jujube.

[0014] The effects of each component of the present invention are as follows:

[0015] Lotus leaf: Neutral in nature and bitter in flavor, it enters the liver, spleen, and stomach meridians, and has the effects of clearing away heat and dampness, promoting the development of clear yang, and cooling blood and stopping bleeding. In this prescription, lotus leaf, as the main ingredient, primarily clears heat and dampness, promotes the development of clear yang, and helps alleviate the dysfunction of the spleen and stomach caused by internal dampness and heat, promoting the excretion of excess water.

[0016] Hawthorn: Sour, sweet, and slightly warm; enters the spleen, stomach, and liver meridians. It helps digestion and strengthens the stomach, promotes qi and dissipates blood stasis, clears turbidity and reduces lipids, and assists the main herb in enhancing digestion, eliminating stagnation, and clearing heat and dampness.

[0017] Poria: sweet, light, neutral, enters the heart, lung, spleen, and kidney meridians, has the functions of promoting diuresis and dispelling dampness, strengthening the spleen and calming the mind, and assisting the main and auxiliary drugs in strengthening the spleen and removing dampness, calming the mind and tranquilizing the nerves.

[0018] Licorice: promotes diuresis and eliminates dampness, strengthens the spleen and removes dampness, further enhancing the effect of strengthening the spleen and removing dampness.

[0019] Tangerine peel: regulates qi and strengthens the spleen, dries dampness and resolves phlegm, harmonizes the spleen and stomach, and guides the medicinal effects to the diseased area.

[0020] Cassia seed: clears the liver and improves eyesight, moistens the intestines and promotes bowel movements, and works synergistically with the main and auxiliary herbs to enhance the effects of clearing heat and promoting diuresis.

[0021] Yam: nourishes the spleen and stomach, promotes fluid production and benefits the lungs, and assists the main and auxiliary medicines in strengthening the spleen and replenishing qi.

[0022] Ginger: warms the middle and dispels cold, harmonizes the stomach and stops vomiting, harmonizes the properties of medicines, and reduces the cold nature of prescriptions.

[0023] Jujube: tonifies the middle and replenishes Qi, harmonizes the spleen and stomach, and together with ginger, plays the role of harmonizing the properties of the medicine and guiding the medicine into the meridians.

[0024] The second aspect of the present invention provides a dosage form of the above-mentioned Chinese medicine composition, including a decoction, granules or capsules.

[0025] That is, the above-mentioned Chinese medicine composition can be directly decocted and taken orally, or can be prepared into Chinese medicine preparations, such as granules or capsules.

[0026] The third aspect of the present invention provides a method for preparing a traditional Chinese medicine preparation having weight loss and lipid-lowering effects, comprising the following steps:

[0027] (1) Preparing medicinal materials: According to weight, weigh 20-30 parts of lotus leaves, 12-24 parts of hawthorn, 15-25 parts of poria cocos, 3-10 parts of liquorice, 5-6 parts of dried tangerine peel, 6-8 parts of cassia seeds, 5-8 parts of yam, 1-3 parts of ginger, and 1-3 parts of jujube, grind them, and then sieve them to obtain a medicinal material mixture;

[0028] (2) Extraction: Soak the medicinal material mixture in water and then heat and reflux to obtain an extract;

[0029] (3) Preparing medicinal powder: drying the extract to obtain medicinal powder;

[0030] (4) Preparation: The drug powder is crushed, mechanically homogenized, sieved, and packed into medicine bags or filled into capsule shells to make capsules.

[0031] Preferably, in (1), the powder is crushed to a particle size of 10-200 μm.

[0032] Preferably, in (2), the mass ratio of the medicinal material mixture to water is 1:10 to 30; more preferably, it is 1:20.

[0033] Preferably, in (2), the soaking time is 0.5-2.5h.

[0034] Preferably, in (2), the temperature of the heating reflux extraction is 100-110°C.

[0035] Preferably, in (2), the number of heating reflux extractions is 1-3 times, and the time for each heating reflux extraction is 0.5-2.5 h.

[0036] Preferably, in (3), drying includes any one of air drying and freeze drying.

[0037] Preferably, the temperature of the forced air drying is 60-100°C.

[0038] Preferably, the pre-freezing temperature of freeze drying is -20°C to -80°C, the sublimation temperature is -10 to 0°C, and the decomposition temperature is 30°C to 60°C.

[0039] The fourth aspect of the present invention provides the use of the above-mentioned traditional Chinese medicine composition in the preparation of a drug for weight loss and lipid reduction.

[0040] The beneficial effects of the present invention are:

[0041] In the medicine-food combination provided by the present invention, in this side, medicines such as lotus leaf, hawthorn, and cassia seed have the effects of removing blood stasis, digesting food, lowering blood lipids, and losing weight, and are monarch and minister medicines for obesity, hyperlipidemia, etc.; medicines such as Poria cocos, liquorice, and dried tangerine peel can invigorate the spleen and eliminate dampness, regulate qi and resolve phlegm, can eliminate the evil of dampness and turbidity in the body, enhance the transportation and transformation function of the spleen and stomach, provide a basis for the monarch and minister medicines to play a role, and also create a good internal environment for the normal metabolism of the body; guiding medicines such as yam, ginger, and jujube can invigorate the spleen and replenish qi, nourish blood and calm the mind, and harmonize various medicines, so that the whole side does not hurt the vital energy while removing evil, and achieves the purpose of removing dampness and removing turbidity, strengthening the spleen and eliminating accumulation, reducing blood lipids and losing weight, and conditioning the body. The whole side has reasonable compatibility, attacks and supplements at the same time, and plays the merits of removing dampness and removing turbidity, strengthening the spleen and eliminating accumulation, and reducing blood lipids and losing weight, and has a good improvement effect on various diseases such as obesity, hyperlipidemia, spleen and stomach food accumulation, dampness and phlegm. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is a Venn diagram of the intersection targets of obesity and the prescription in Example 1 of the present invention;

[0043] Figure 2 This is an interaction correlation diagram for the prescription for treating obesity in Example 1 of the present invention;

[0044] Figure 3 This is a PPI network association diagram for the prescription for treating obesity in Example 1 of the present invention;

[0045] Figure 4 This is a graph showing the effects of each formula in Example 2 of the present invention on four blood lipid parameters in hyperlipidemia model C57 / 6J mice;

[0046] Note: Compared with the normal control group, *P<0.05, **P<0.01; compared with the model control group, #P<0.05, ##P<0.01.

[0047] Figure 5 This is a graph showing the effect of the optimal prescription in Example 2 of the present invention on the body weight of mice in each dosage group; Note: Compared with the normal control group, *P<0.05, **P<0.01; compared with the model control group, #P<0.05, ##P<0.01. DETAILED DESCRIPTION

[0048] To make the objectives, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.

[0049] Unless otherwise specified, the test materials and reagents used in the following examples can be obtained from commercial sources.

[0050] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the quantitative tests in the following examples were repeated three times and the results were averaged.

[0051] Example 1: Prescription analysis using network pharmacology big data

[0052]

Experimental principles and methods

[0053] Network pharmacology is an emerging discipline that is based on systems biology, proteomics and genomics. It mainly explores the interaction network between "drug-target-gene-disease phenotype". The present invention focuses on conducting in-depth research on the four main medicinal materials in the composition. First, the chemical composition of the medicinal materials is analyzed and the key active ingredients are accurately identified. Then, with the help of network pharmacology and bioinformatics technology, the potential targets of its components are screened on a large scale to construct a component-target network. Subsequent pathway enrichment analysis was carried out to deeply explore the targets and genes that are closely related to the occurrence and development of obesity, providing key theoretical support for the development and optimization of the composition and pointing out the direction for subsequent drug research and development.

[0054]

Experimental Materials

[0055] Table 1: Network pharmacology related databases

[0056]

[0057]

[0058]

Experimental results

[0059] from Figure 1 The analysis showed that the medicinal materials of the present invention screened out 820 targets, of which 347 targets related to obesity were enriched. The STRING database was used to process the 347 potential targets of the prescription for treating obesity, and the interaction correlation diagram of the prescription for treating obesity was obtained ( Figure 2 ), of which the number of nodes is 301 and the number of edges is 1183. After four median screenings, the core target genes screened out are STAT3, SRC, MAPK1, AKT1, ESR1, TP53, JUN Figure 3 ;

[0060] The screened core targets and the top 10 pathways in the bubble chart (Table 2) are mostly closely related to the glucose and lipid metabolism process. From the perspective of big data bioinformatics analysis, this fully demonstrates the rationality of the formula of the present invention and its potential to assist in weight loss.

[0061] Table 2: Bubble chart of the top 10 pathway entry names

[0062] Term GO-BP or Pathway name Log(q-value) Insulin resistance Insulin resistance -16.29123264 Lipid and atherosclerosis Lipid metabolism and atherosclerosis -16.04511492 Fluid shear stress and atherosclerosis Fluid shear stress and atherosclerosis -13.66579592 AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications -13.66579592 Non-alcoholic fatty liver disease Nonalcoholic fatty liver disease -11.67506461 HIF-1 signaling pathway HIF-1 signaling pathway -11.67506461 Alcoholic liver disease Alcoholic liver disease -10.57535694 Proteoglycans in cancer Proteoglycans in cancer -10.57535694 Diabetic cardiomyopathy Diabetic cardiomyopathy -10.57535694

[0063] Example 2: Optimal formula screening experiment

[0064] Formula 1: Lotus leaf: 30 parts, Hawthorn: 24 parts, Poria: 20 parts, Licorice: 10 parts, Tangerine peel: 5 parts, Cassia seed: 6 parts, Chinese yam: 8 parts, Ginger: 3 parts, Jujube: 1 part.

[0065] Recipe 2: Lotus leaf: 20 parts, Hawthorn: 12 parts, Poria: 15 parts, Licorice: 3 parts, Tangerine peel: 6 parts, Cassia seed: 7 parts, Chinese yam: 5 parts, Ginger: 2 parts, Jujube: 2 parts.

[0066] Formula three: lotus leaf: 24 parts, hawthorn: 20 parts, poria: 24 parts, licorice: 6 parts, tangerine peel: 6 parts, cassia seed: 8 parts, yam: 6 parts, ginger: 3 parts, jujube: 3 parts.

[0067] The preparation method is:

[0068] (1) Prepare medicinal materials: weigh each component according to the above weight parts;

[0069] (2) grinding to a particle size of 10-200 μm and then sieving to obtain a medicinal material mixture;

[0070] (3) Extraction: Soak the medicinal material mixture in water and then heat and reflux to obtain an extract; the mass ratio of the medicinal material mixture to water is 1:10-30; the soaking time is 0.5-2.5 hours; the temperature of the heating and reflux extraction is 100-110°C; the number of heating and reflux extractions is 1-3 times, and the time of each heating and reflux extraction is 0.5-2.5 hours;

[0071] (4) Preparation of medicinal powder: freeze-dry the extract (pre-freezing temperature is -20°C to -80°C, sublimation temperature is -10°C to 0°C, and decomposition temperature is 30°C to 60°C) to obtain medicinal powder; the medicinal powder can be used in experiments; and the medicinal liquid is prepared according to a mass ratio of 1:2 between the medicinal powder and water.

[0072]

Experimental methods

[0073] 1. Experimental Animals

[0074] Forty C57BL / 6J male mice, specific pathogen-free (SPF) grade, weighing (18 ± 2) g, were purchased from Henan Sikebes Biotechnology Co., Ltd., production license number: SCXK 2020-0005. Animal experiments were conducted in accordance with the ethical regulations and procedures of the Wanbei Coal and Electricity General Hospital Committee.

[0075] 2. Experimental Materials

[0076] Ordinary mouse feed (19.2% protein, 67.3% carbohydrates, 4.3% fat) and high-fat feed (26% protein, 26% carbohydrates, 35% fat) were purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd.

[0077] 3. Modeling method

[0078] The experimental animals were raised under controlled environmental conditions, specifically: room temperature (22±4)°C, relative humidity (60±10)%, and a 12-hour light / 12-hour dark cycle. The animals first received a one-week adaptive feeding of ordinary feed. Subsequently, the experimental group of mice was fasted for 24 hours and began to be fed a high-fat diet (60% fat calories) to induce the establishment of an obesity model. After the adaptive feeding was completed, the mice were randomly divided into 5 groups of 8 each, and the specific groups were as follows:

[0079] ① Normal diet group: fed with ordinary feed and gavaged with equal volume of distilled water.

[0080] ② High-fat diet group: fed with high-fat feed and gavaged with equal volume of distilled water.

[0081] ③Formula 1: Feeding with high-fat feed, oral administration of Formula 1.

[0082] ④Formula 2: Feed with high-fat feed, and administer Formula 2 by gavage.

[0083] ⑤Formula 3: Feed with high-fat feed, and administer formula 3 by gavage.

[0084] Dosage Group: Based on the human dose conversion (100g of crude drug / day, calculated based on a 70kg body weight) and the equivalent dose conversion formula for humans and animals, the mouse dose was determined to be 15.6mg / kg. The gavage volume was 0.1mL / 10g body weight. During the experiment, the mice drank water and ate food normally. The model was established and the drug was administered by gavage continuously for 8 weeks. During the dosing period, the survival status of the mice in each group was observed, and their body weight, water intake, and food intake were recorded regularly.

[0085]

Experimental steps

[0086] After administration, the animals in each group were fixed in the supine position, and venous blood was collected and centrifuged at 1500 rpm for 15 minutes to separate the serum. Serum was then collected to measure the levels of cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C).

[0087]

Experimental results

[0088] The TC, TG, and LDL-C levels of mice in the high-fat diet group were significantly higher than those in the normal diet group, while HDL-C levels were significantly lower, indicating that the obesity model was successfully induced. In contrast, Formula 1, Formula 2, and Formula 3 were all able to effectively reduce blood lipid indicators (TC, TG, LDL-C) and increase HDL-C levels, with Formula 3 having the most significant regulatory effect (see Figure 4 Therefore, the third formulation was selected as the optimal formulation for the subsequent pharmacodynamic experiments.

[0089] Example 3: Pharmacodynamic evaluation of the optimal formula for assisting weight loss

[0090] The optimal formulation selected in Example 2 was selected for pharmacodynamic evaluation to confirm the efficacy of the medicine-food formulation in assisting the treatment of obesity.

[0091] The preparation of the drug powder and the drug solution is the same as in Example 2.

[0092] Animal grouping and drug administration

[0093] Forty C57BL / 6J male mice, specific pathogen-free (SPF) grade, weighing (18 ± 2) g, were purchased from Henan Sikebes Biotechnology Co., Ltd., production license number: SCXK 2020-0005. Animal experiments were conducted in accordance with the ethical regulations and procedures of the Wanbei Coal and Electricity General Hospital Committee.

[0094] Modeling method

[0095] The experimental animals were raised under controlled environmental conditions, specifically: room temperature (22±4)°C, relative humidity (60±10)%, and a 12-hour light / 12-hour dark cycle. The animals first received a one-week adaptive feeding of ordinary feed. Subsequently, the experimental group of mice was fasted for 24 hours and began to be fed a high-fat diet (60% fat calories) to induce the establishment of an obesity model. After the adaptive feeding was completed, the mice were randomly divided into 4 groups, 10 in each group, and the specific groups were as follows:

[0096] ① Normal diet group (NC group): fed with normal feed and gavaged with equal volume of distilled water.

[0097] ② High-fat diet group (HFD group): fed with high-fat feed and gavaged with an equal volume of distilled water.

[0098] ③The best formula group (ZYF group): fed with high-fat feed and gavaged with the three extracts of the formula.

[0099] ④ Positive drug control group (OTC group): fed with high-fat feed and orlistat was administered orally.

[0100] Dosage groups (OTC group and ZYF group): Based on the human dose conversion (100g crude drug / day, calculated based on 70kg body weight) and the equivalent dose conversion formula between humans and animals, the mouse dosage of ZYF-G high-dose group was determined to be 35.88mg / kg, and a ZYF-L low-dose group (8.97mg / kg) and a ZYF-M medium-dose group (17.94mg / kg) were set up. The gavage volume was 0.1mL / 10g body weight. During the experiment, the mice drank water and ate normally, and the model was established and gavage was administered for 8 weeks. During the dosing period, the survival status of the mice in each group was observed, and their body weight, water intake, and food intake were recorded regularly.

[0101] After administration, mice were fasted but not deprived of water for 24 hours. They were then anesthetized, blood was collected from their eyeballs, and they were killed by cervical dislocation. The mice were dissected, and their livers, kidneys, and white adipose tissue (including epididymal fat and perirenal fat) were removed. The liver and epididymal adipose tissue were fixed with a fixative, while the remaining tissues were quickly frozen in liquid nitrogen and stored at -80°C. At the same time, the liver and adipose tissue were dissected, and the liver and fat weights were weighed. The fat coefficient was calculated according to formula (2).

[0102]

[0103] Experimental results

[0104] (1) The changes in body weight of mice in each group are shown in Figure 5 .

[0105] The results showed that after eight weeks of oral administration, the body weight of mice in each group decreased to varying degrees. At week 8, the body weight of mice in the HFD group was significantly higher than that in the NC group (P < 0.01). The body weight of mice in the low-dose ZYF-L group (8.97 mg / kg), the medium-dose ZYF-M group (17.94 mg / kg), the high-dose ZYF-G group (35.88 mg / kg), and the OTC group was significantly lower than that in the HFD group (P < 0.05 or P < 0.01). Overall, the results showed that all drug-administered groups were effective, with the ZYF-G group showing the greatest effect.

[0106] (2) The fat coefficient results of each group of mice are shown in Table 3.

[0107] Table 3

[0108] Group Fat index (%) NC group 1.08±0.12 HFD group 2.17±0.41** ZYF-L group 1.81±0.35 ZYF-M group 1.58±0.39## ZYF-G group 1.37±0.30## OTC Group 1.56±0.35##

[0109] Note: Compared with the normal control group, **P<0.01; compared with the model control group, #P<0.05, ##P<0.01.

[0110] The results showed that the fat coefficient of the model control group was significantly higher than that of the normal control group (P<0.01).

[0111] This study once again proved that the high-fat model provided by the ZYF-G group was the best (P<0.01). The effects of the ZYF-L and ZYF-M groups were not significant.

[0112] In summary, the medicine-food composition provided in this application can effectively reduce blood lipids and lose weight.

[0113] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. A Chinese medicine composition with weight loss and lipid-lowering effects, characterized in that: Calculated on the basis of the raw materials, the invention comprises the following components in parts by weight: 20-30 parts of lotus leaves, 12-24 parts of hawthorn, 15-25 parts of poria, 3-10 parts of liquorice, 5-6 parts of tangerine peel, 6-8 parts of cassia seeds, 5-8 parts of yam, 1-3 parts of ginger, and 1-3 parts of jujube.

2. The Chinese medicine composition according to claim 1, characterized in that Calculated on the basis of raw materials, the preparation includes the following components in parts by weight: 30 parts of lotus leaves, 24 parts of hawthorn, 20 parts of poria, 10 parts of licorice, 5 parts of tangerine peel, 6 parts of cassia seeds, 8 parts of yam, 3 parts of ginger, and 1 part of jujube.

3. The Chinese medicine composition according to claim 1, characterized in that Calculated on the basis of raw materials, the preparation includes the following components in parts by weight: 24 parts of lotus leaves, 20 parts of hawthorn, 24 parts of poria, 6 parts of licorice, 6 parts of tangerine peel, 8 parts of cassia seeds, 6 parts of yam, 3 parts of ginger, and 3 parts of jujube.

4. A dosage form of the Chinese medicine composition according to claim 1, characterized in that: Including water decoction, granules or capsules.

5. A method for preparing a traditional Chinese medicine preparation having weight loss and lipid-lowering effects, characterized in that: The following steps are involved: (1) Preparing medicinal materials: According to weight, weigh 20-30 parts of lotus leaves, 12-24 parts of hawthorn, 15-25 parts of poria cocos, 3-10 parts of liquorice, 5-6 parts of dried tangerine peel, 6-8 parts of cassia seeds, 5-8 parts of yam, 1-3 parts of ginger, and 1-3 parts of jujube, grind them, and then sieve them to obtain a medicinal material mixture; (2) Extraction: Soak the medicinal material mixture in water and then heat and reflux to obtain an extract; (3) Preparing medicinal powder: drying the extract to obtain medicinal powder; (4) Preparation: The drug powder is crushed, mechanically homogenized, sieved, and packed into medicine bags or filled into capsule shells to make capsules.

6. The preparation method according to claim 5, characterized in that (1), crushed to a particle size of 10-200 μm.

7. The preparation method according to claim 5, characterized in that (2), the mass ratio of the medicinal material mixture to water is 1:10-30; and the soaking time is 0.5-2.5h.

8. The preparation method according to claim 5, characterized in that In (2), the temperature of the heating reflux extraction is 100-110° C.; in (2), the number of heating reflux extractions is 1-3 times, and the time of each heating reflux extraction is 0.5-2.5 h.

9. The preparation method according to claim 5, characterized in that In (3), the drying includes either forced air drying or freeze drying; the temperature of forced air drying is 60-100°C; the pre-freezing temperature of freeze drying is -20°C to -80°C, the sublimation temperature is -10 to 0°C, and the decomposition temperature is 30°C to 60°C.

10. Use of the traditional Chinese medicine composition according to claim 1 in the preparation of drugs for weight loss and lipid reduction.

Images